Do analysts prefer CNNE or CNTN?

Cannae currently has a consensus target price of $17.00, indicating a potential upside of 9.45%. Given Cannae's stronger consensus rating and higher probable upside, analysts clearly believe Cannae is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cannae 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CNNE or CNTN?

In the previous week, Cannae and Cannae both had 2 articles in the media. Hillstream Biopharma's average media sentiment score of 1.28 beat Cannae's score of 0.53 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cannae 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TRON or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TRON or CNTN?

In the previous week, Tron had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 6 mentions for Tron and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Tron's score of 0.42 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tron 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hillstream Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FWDI or CNTN?

Forward Industries presently has a consensus target price of $13.50, suggesting a potential upside of 83.92%. Given Forward Industries' stronger consensus rating and higher probable upside, analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forward Industries 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer FWDI or CNTN?

In the previous week, Forward Industries had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Forward Industries and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Forward Industries' score of 0.45 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forward Industries 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hillstream Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CNTN or ACTG?

Acacia Research has a consensus target price of $6.00, indicating a potential upside of 38.89%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts clearly believe Acacia Research is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acacia Research 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CNTN or ACTG?

In the previous week, Acacia Research had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Acacia Research and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Acacia Research's score of 0.61 indicating that Hillstream Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acacia Research 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CNTN or CEPO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CNTN or CEPO?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$0.50 N/A Cantor Equity Partners N/A N/A -$6.66M -$0.29 N/A

Is CNTN or CEPO more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -20.06% -15.90% Cantor Equity Partners N/A N/A -0.74%

Does the media favor CNTN or CEPO?

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Cantor Equity Partners and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Cantor Equity Partners' score of 0.83 indicating that Hillstream Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cantor Equity Partners 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hillstream Biopharma (CNTN) Competitors

$2.11 +0.03 (+1.44%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.12 +0.01 (+0.24%)

As of 10/9/2026 07:30 PM Eastern

Compare

CNTN vs. CNNE, TRON, FWDI, ACTG, and CEPO

Should you buy Hillstream Biopharma stock or one of its competitors? Hillstream Biopharma's main competitors and comparable companies include Cannae (CNNE), Tron (TRON), Forward Industries (FWDI), Acacia Research (ACTG), and Cantor Equity Partners (CEPO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Hillstream Biopharma compare to Cannae?

Cannae (NYSE:CNNE) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Cannae has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Hillstream Biopharma has lower revenue, but higher earnings than Cannae. Cannae is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannae	$423.60M	1.59	-$513.20M	-$3.02	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

In the previous week, Cannae and Cannae both had 2 articles in the media. Hillstream Biopharma's average media sentiment score of 1.28 beat Cannae's score of 0.53 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cannae	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cannae currently has a consensus target price of $17.00, indicating a potential upside of 9.45%. Given Cannae's stronger consensus rating and higher probable upside, analysts clearly believe Cannae is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannae	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

88.1% of Cannae shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 10.9% of Cannae shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Hillstream Biopharma has a net margin of 0.00% compared to Cannae's net margin of -38.18%. Cannae's return on equity of -14.10% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cannae	-38.18%	-14.10%	-10.60%
Hillstream Biopharma	N/A	-20.06%	-15.90%

Summary

Cannae beats Hillstream Biopharma on 8 of the 14 factors compared between the two stocks.

How does Hillstream Biopharma compare to Tron?

Tron (NASDAQ:TRON) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tron had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 6 mentions for Tron and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Tron's score of 0.42 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tron	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hillstream Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tron has a beta of 8.69, indicating that its stock price is 769% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Tron has a net margin of 135.58% compared to Hillstream Biopharma's net margin of 0.00%. Tron's return on equity of -5.60% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tron	135.58%	-5.60%	-5.53%
Hillstream Biopharma	N/A	-20.06%	-15.90%

Tron has higher revenue and earnings than Hillstream Biopharma. Tron is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tron	$4.74M	125.60	-$16.81M	-$0.11	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

28.0% of Tron shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 86.2% of Tron shares are held by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Tron beats Hillstream Biopharma on 10 of the 12 factors compared between the two stocks.

How does Hillstream Biopharma compare to Forward Industries?

Forward Industries (NASDAQ:FWDI) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

1.2% of Hillstream Biopharma shares are held by institutional investors. 15.9% of Forward Industries shares are held by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Forward Industries had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Forward Industries and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Forward Industries' score of 0.45 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forward Industries	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hillstream Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hillstream Biopharma has a net margin of 0.00% compared to Forward Industries' net margin of -2,073.82%. Forward Industries' return on equity of -18.05% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forward Industries	-2,073.82%	-18.05%	-17.03%
Hillstream Biopharma	N/A	-20.06%	-15.90%

Hillstream Biopharma has lower revenue, but higher earnings than Forward Industries. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Forward Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forward Industries	$18.19M	29.80	-$166.97M	$0.12	61.17
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A

Forward Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Forward Industries presently has a consensus target price of $13.50, suggesting a potential upside of 83.92%. Given Forward Industries' stronger consensus rating and higher probable upside, analysts plainly believe Forward Industries is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forward Industries	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Forward Industries beats Hillstream Biopharma on 9 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Acacia Research?

Hillstream Biopharma (NASDAQ:CNTN) and Acacia Research (NASDAQ:ACTG) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Acacia Research had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Acacia Research and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Acacia Research's score of 0.61 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acacia Research	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hillstream Biopharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Acacia Research has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Acacia Research has higher revenue and earnings than Hillstream Biopharma. Acacia Research is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Acacia Research	$285.23M	1.48	$21.68M	-$0.15	N/A

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 86.7% of Acacia Research shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 1.7% of Acacia Research shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hillstream Biopharma has a net margin of 0.00% compared to Acacia Research's net margin of -5.39%. Acacia Research's return on equity of 0.44% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Acacia Research	-5.39%	0.44%	0.33%

Acacia Research has a consensus target price of $6.00, indicating a potential upside of 38.89%. Given Acacia Research's stronger consensus rating and higher possible upside, analysts clearly believe Acacia Research is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acacia Research	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Acacia Research beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Cantor Equity Partners?

Hillstream Biopharma (NASDAQ:CNTN) and Cantor Equity Partners (NASDAQ:CEPO) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Hillstream Biopharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Cantor Equity Partners has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Cantor Equity Partners and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.28 beat Cantor Equity Partners' score of 0.83 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cantor Equity Partners	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$0.50	N/A
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.29	N/A

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-20.06%	-15.90%
Cantor Equity Partners	N/A	N/A	-0.74%

Summary

Hillstream Biopharma and Cantor Equity Partners tied by winning 5 of the 10 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$168.13M	$27.73B	$13.16B	$13.30B
Dividend Yield	N/A	6.94%	6.08%	22.58%
P/E Ratio	-4.22	19.42	24.73	26.14
Price / Sales	N/A	332.68	487.17	87.88
Price / Cash	N/A	266.54	46.65	53.71
Price / Book	0.19	3.29	2.71	6.33
Net Income	-$35.92M	$1.12B	$1.32B	$382.15M
7 Day Performance	-6.22%	0.12%	-0.51%	-1.40%
1 Month Performance	N/A	-1.17%	-2.62%	-3.35%
1 Year Performance	N/A	-10.53%	10.49%	1.49%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.3495 of 5 stars	$2.11 +1.4%	N/A	N/A	$168.13M	N/A	N/A	12	News Coverage
CNNE Cannae	1.938 of 5 stars	$15.50 -0.6%	$16.50 +6.4%	-14.3%	$676.20M	$423.60M	N/A	6,602	News Coverage Positive News Analyst Downgrade
TRON Tron	0.0782 of 5 stars	$1.29 -4.4%	N/A	-63.2%	$640.42M	$5.06M	N/A	7
FWDI Forward Industries	3.5733 of 5 stars	$8.14 +0.4%	$13.50 +65.8%	N/A	$598.90M	$18.19M	67.83	60
ACTG Acacia Research	2.7927 of 5 stars	$4.37 +1.6%	$6.00 +37.3%	+28.6%	$419.62M	$278.37M	N/A	986	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. CNNE, TRON, FWDI, ACTG, and CEPO

How does Hillstream Biopharma compare to Cannae?

Summary

How does Hillstream Biopharma compare to Tron?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. CNNE, TRON, FWDI, ACTG, and CEPO

How does Hillstream Biopharma compare to Cannae?

Which has more risk and volatility, CNNE or CNTN?

Which has preferable earnings & valuation, CNNE or CNTN?

Does the media prefer CNNE or CNTN?

Do analysts prefer CNNE or CNTN?

Do institutionals and insiders believe in CNNE or CNTN?

Is CNNE or CNTN more profitable?

Summary

How does Hillstream Biopharma compare to Tron?

Do analysts recommend TRON or CNTN?

Does the media prefer TRON or CNTN?

Which has more volatility & risk, TRON or CNTN?

Is TRON or CNTN more profitable?

Which has higher valuation and earnings, TRON or CNTN?

Do institutionals & insiders have more ownership in TRON or CNTN?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Do insiders and institutionals hold more shares of FWDI or CNTN?

Does the media prefer FWDI or CNTN?

Is FWDI or CNTN more profitable?

Which has stronger earnings and valuation, FWDI or CNTN?

Which has more risk & volatility, FWDI or CNTN?

Do analysts recommend FWDI or CNTN?

Summary

How does Hillstream Biopharma compare to Acacia Research?

Does the media refer more to CNTN or ACTG?

Which has more volatility & risk, CNTN or ACTG?

Which has stronger valuation & earnings, CNTN or ACTG?

Do insiders and institutionals have more ownership in CNTN or ACTG?

Is CNTN or ACTG more profitable?

Do analysts rate CNTN or ACTG?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Which has more risk and volatility, CNTN or CEPO?

Do analysts recommend CNTN or CEPO?

Do insiders & institutionals have more ownership in CNTN or CEPO?

Does the media favor CNTN or CEPO?

Which has higher earnings and valuation, CNTN or CEPO?

Is CNTN or CEPO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools